Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Nov-Dec;47(6):616-9.
doi: 10.4103/0253-7613.169571.

Metabolic effects as a cause of myotoxic effects of fluoroquinolones

Thomas Metterlein  1 , Frank Schuster  2 , Martin Hager  2 , Norbert Roewer  2 , Martin Anetseder  3
Affiliations
Comparative Study

Metabolic effects as a cause of myotoxic effects of fluoroquinolones

Thomas Metterlein et al. Indian J Pharmacol. 2015 Nov-Dec.

Abstract

Objectives: To investigate if fluoroquinolones (FQs) influence skeletal muscle metabolism of healthy and malignant hyperthermia susceptible (MHS) pigs.

Materials and methods: After approval from of the Animal Care Committee, 10 MHS pigs, and 6 MHS pigs were anesthetized with hemodynamic and systemic metabolic monitoring. Microdialysis catheters were placed intramuscularly. After equilibration, levofloxacin and ciprofloxacin were injected as a rapid bolus and continuous infusions. Lactate was measured in the dialysate and statistically analyzed was done (Wilcoxon-test; U-test; P < 0.05).

Results: There were no differences in age, weight, and baseline lactate levels between the groups. Both applications of levofloxacin- and ciprofloxacin-induced an increase of local lactate levels in healthy and MHS pigs. No difference between the two groups was observed.

Conclusion: FQs influence skeletal muscle metabolism. Myotoxic effects of FQs can, therefore, be explained by an influence on the cellular energy balance.

Keywords: Fluoroquinolones; malignant hyperthermia; metabolism; myotoxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lactate levels after bolus application of levofloxacin and ciprofloxacin (Wilcoxon rank sum test; *P < 0.05)
Figure 2
Figure 2
Lactate levels after continuous application of levofloxacin and ciprofloxacin (Wilcoxon rank sum test; *P < 0.05)
See this image and copyright information in PMC

References

    1. Bolon MK. The newer fluoroquinolones. Infect Dis Clin North Am. 2009;23:1027–51. x. - PubMed
    1. Guis S, Bendahan D, Kozak-Ribbens G, Mattei JP, Le Fur Y, Confort-Gouny S, et al. Investigation of fluoroquinolone-induced myalgia using (31) P magnetic resonance spectroscopy and in vitro contracture tests. Arthritis Rheum. 2002;46:774–8. - PubMed
    1. Guis S, Jouglard J, Kozak-Ribbens G, Figarella-Branger D, Vanuxem D, Pellissier JF, et al. Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment. J Rheumatol. 2001;28:1405–6. - PubMed
    1. Petitjeans F, Nadaud J, Perez JP, Debien B, Olive F, Villevieille T, et al. A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin. Eur J Clin Pharmacol. 2003;59:779–80. - PubMed
    1. Hsiao SH, Chang CM, Tsao CJ, Lee YY, Hsu MY, Wu TJ. Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy. Ann Pharmacother. 2005;39:146–9. - PubMed

Publication types

MeSH terms